FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma Performance status 0 (n=42) (vs. PS 2) 0.19 0.05 - 0.72 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results